FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

The FDA's approval of Bristol Myers Squibb's Zenbexus marks the debut of a new class of drugs for treating multiple myeloma. The drug is approved for use in combination with Daratumumab and Dexamethasone, as early as the first relapse. The approval is significant because it introduces a novel mechanism of action, known as CELMoD, which may offer new benefits for patients. The approval is the result of Bristol Myers Squibb's development of Zenbexus, a CELMoD therapy.

The drug is designed to work in combination with existing treatments, potentially improving outcomes for patients with multiple myeloma. The FDA granted accelerated approval, indicating a pressing need for new treatments in this area. The approval is noted by Reuters, STAT, and Fierce Pharma, among others. The approval raises questions about the future of Bristol Myers Squibb's stock.

Yahoo Finance questions whether the stock is fully priced, suggesting that investors may be uncertain about the long-term impact of the approval. The approval of Zenbexus could lead to increased revenue for Bristol Myers Squibb, but the stock's current valuation may already reflect this potential.